title: Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulation?
abstract: The ability to predict the response potential of women to ovarian stimulation may allow the development of individualized ovarian stimulation protocols. This tailored approach to ovarian stimulation could reduce the incidence of ovarian hyperstimulation syndrome in women predicted to have an excessive response to stimulation or could improve pregnancy outcomes in women classed as poor responders. Namely, variation of the type of gonadotrophin-releasing hormone (GnRH) analogue or the form and dosage of gonadotrophin used for stimulation could be adjusted according to an individual's response potential. The serum concentration of anti-Müllerian hormone (AMH) is established as a reliable marker of ovarian reserve, with decreasing concentrations correlated with reduced response potential. This review examines the current evidence evaluating individualized ovarian stimulation protocols using AMH concentration as a predictive marker of ovarian response. The rationale behind why specific treatment protocols based on individual response potential may be more suitable is also discussed. Based on current evidence, it appears that the use of AMH serum concentrations to predict ovarian response and optimize treatment strategies is a promising approach for improving pregnancy outcomes in women undergoing ovarian stimulation. However, prospective randomized controlled trials evaluating this approach are needed before any firm conclusions can be drawn.
authors.affiliation: Glasgow Centre for Reproductive Medicine (GCRM) Ltd., Glasgow, UK. Richard.Fleming@gcrm.co.uk
authors.forename: R
authors.initials: R
authors.lastname: Fleming
authors.forename: F
authors.initials: F
authors.lastname: Broekmans
authors.forename: C
authors.initials: C
authors.lastname: Calhaz-Jorge
authors.forename: L
authors.initials: L
authors.lastname: Dracea
authors.forename: H
authors.initials: H
authors.lastname: Alexander
authors.forename: A
authors.initials: A
authors.lastname: Nyboe Andersen
authors.forename: C
authors.initials: C
authors.lastname: Blockeel
authors.forename: J
authors.initials: J
authors.lastname: Jenkins
authors.forename: B
authors.initials: B
authors.lastname: Lunenfeld
authors.forename: P
authors.initials: P
authors.lastname: Platteau
authors.forename: J
authors.initials: J
authors.lastname: Smitz
authors.forename: D
authors.initials: D
authors.lastname: de Ziegler
mesh_terms: D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006062:Gonadotropins / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control; D010053:Ovary / Q000187:drug effects / Q000502:physiology; D010062:Ovulation Induction / Q000379:methods*; D011237:Predictive Value of Tests; D015203:Reproducibility of Results
chemical_list: D015415:Biomarkers; D006062:Gonadotropins; D054304:Anti-Mullerian Hormone